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R1009Tumor Microenvironment: Unleashing
Metalloproteinases to Induce a CAF
PhenotypePathologically activated fibroblasts have been shown to play a role in fibrotic
disorders and cancer, but the molecular mechanisms regulating their
emergence are still poorly characterized. A recent study demonstrates that
unleashing metalloproteinase activity in fibroblasts is sufficient for the
acquisition of an activated pro-tumorigenic phenotype.Nicola Ferrari and Fernando Calvo*
Stromal cells and extracellular
matrix (ECM) molecules within the
tumor — collectively defined as
the tumor microenvironment
[1] — participate in many of
the hallmarks of cancer [2].
Cancer-associated fibroblasts (CAFs)
are non-malignant cells found in many
solid tumors that provide a chemical
and physical microenvironment that
can favor tumor aggressiveness and
dissemination [3,4]. Unlike normal
fibroblasts, CAFs present a
pathologically activated phenotype
that is responsible for their
pro-tumorigenic activities. This
phenotype is also found in fibroblasts
in fibrotic disorders and is reminiscent
of the activated status observed in
fibroblasts during wound healing.
Despite the major role of CAFs in
tumor progression and their influence
in overall patient survival [3,5], the
molecular rearrangements leading
to the altered CAF state are not well
understood. A new study by
Shimoda et al. [6] now demonstrates
that deletion of a family of
metalloproteinase inhibitors is
sufficient for the acquisition of an
activated fibroblast phenotype that
promotes cancer progression through
the production of exosomes.
The metzincin superfamily of
proteases comprises several families
of endopeptidases that include matrix
metalloproteinases (MMPs) and
adamalysins (ADAM), among others.
By influencing the ECM, cell–adhesion
molecules and soluble factors,
proteinases participate in many
physiological and pathological
processes [7]. Due to their potent
activity on signaling and ECM
remodeling, proteinases are tightly
regulated at the transcriptional and
post-translational levels. Tissue
inhibitors of metalloproteinases(TIMPs) are one of the main regulators
of metzincin proteases [8]. The roles of
TIMPs in both normal development and
pathological processes have been
investigated by gene deletion studies in
mice, revealing some functional
redundancy between different
TIMPs [9].
To identify new fundamental
functions mediated by TIMPs and to
avoid any compensatory effects
between different isoforms, Shimoda
et al. [6] generated a mouse lacking all
four Timp genes [6]. These quadruple
Timp-deficient (TIMPless) mice
showed widespread developmental
problems that hindered any cancer
study but that underline an essential
role for TIMPs in normal development
that will need to be explored in the
future.
Due to the early lethality of TIMPless
mice, primary dermal fibroblasts were
derived and used throughout the study
as a model to investigate the impact of
TIMPs on fibroblast activation. Using
a-smooth muscle actin (a-SMA) as
readout, it was observed that only
deletion of all Timp genes led to a
significant activation. Timp1–4 loss in
fibroblasts led to the acquisition of
CAF-like features, as shown by
increased collagen contractility and
expression of activation markers, such
as a-SMA, stromal-derived factor 1
(SDF-1) and transforming growth factor
b2 (TGF-b2). Importantly, when
co-injected with human breast, lung
and head-and-neck cancer cells,
TIMPless fibroblasts promoted primary
tumor growth, angiogenesis and
metastasis in vivo.
Pro-tumorigenic functions of CAFs
have generally been associated with
the production of ECM components or
soluble factors [3,4]. The findings by
Shimoda et al. [6] highlight the
importance of exosomes as a new
mode of intercellular communication in
tumor progression and complementrecent studies demonstrating that
fibroblast-secreted exosomes
accelerate breast cancer metastasis
through induction of Wnt–planar cell
polarity signaling in cancer cells [10].
Exosomes are small vesicles that are
constitutively released by exocytosis
and that act as potent intercellular
communicators, delivering proteins,
mRNA and microRNAs to neighboring
and distant cells [11]. The authors
provide compelling evidence that
exosomes produced by TIMPless
fibroblasts were responsible for their
increased tumorigenic abilities. In
particular, treatment with exosomes
derived from TIMPless fibroblasts
enhanced cancer cell motility through
RhoA activation, and induced cancer
stem cell phenotypes via stimulation of
Notch signaling (Figure 1). A thorough
characterization of the proteomic
content of the exosomes produced by
TIMPless and wild-type fibroblasts
identified several proteins enriched in
TIMPless exosomes. One specific
factor — the transmembrane
metalloproteinase ADAM10 — was
found to be responsible for the
pro-tumorigenic activities of the
TIMPless exosomes because ADAM10
inhibition abrogated both RhoA and
Notch activation induced by exosome
treatment. Significantly, knocking




Although the underlying mechanism
behind the generation of
ADAM10-enriched exosomes in
response to Timp1-4 loss still needs
clarification, the activity of these
exosomesmay have wider implications
(Figure 1). Exosomes produced by
cancer cells have been shown to
participate in the recruitment and
modulation of other stromal cells, such
as bone marrow progenitors and
immune cells, both locally and
systemically [12]. Whether TIMPless
exosomes also interact with adjacent
non-malignant cells is a possibility that
merits further investigation. Both Notch
signaling and Rho activation can
regulate CAF activities [13,14],
suggesting that ADAM10-enriched
exosomes may contribute to the
maintenance of a CAF phenotype
and/or to the activation of adjacent
normal fibroblasts. Mass spectrometry
analysis showed that TIMPless





























Figure 1. TIMPless fibroblasts as multifunctional regulators of tumor progression through exo-
some production.
Loss of Timp family members is sufficient for the acquisition of a CAF-like state in fibroblasts
by unknown mechanisms (1, black arrow). TIMPless fibroblasts generate ADAM10-rich exo-
somes, which enhance cancer cell motility through RhoA activation and induce cancer stem
cell phenotypes via Notch signaling stimulation (2, black arrow). In red, hypothetical functions
of ADAM10-rich exosomes in the tumor microenvironment. ADAM10-rich exosomes may have
local functions on normal or activated fibroblasts (3), paracrine activities on other stromal cell
types (4), or regulate ECM composition and remodeling (5) and thereby have indirect effects
over multiple tumor microenvironment components. ADAM10-rich exosomes may also have
distant effects and contribute to the conditioning of pre-metastatic niches (6). These functions
may be dependent on their signaling or ECM-modifying capabilities.
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Thus, exosomes may also modulate
ECM composition, which, in turn, will
subsequently affect other tumoral
components. These activities may also
be relevant in other scenarios where
protease dysregulation and
pathological fibroblast activation have
been observed, such as fibrosis and
inflammation. Furthermore, the
activities of CAF-derived exosomes
may not only be confined to the local
environment but could also have
systemic effects and participate in the
conditioning of metastatic niches [12].
In support of this hypothesis, TIMPless
exosomes are enriched in tenascin C, a
glycoprotein that supports metastatic
spread through niche formation [15].
These findings from murine primary
fibroblasts were in part recapitulated in
clinical settings [6]. Analysis of CAFs
derived from human head-and-neck
squamous cell carcinoma indicated
that they also produced ADAM10-rich
exosomes. Similar to TIMPless
fibroblasts, these exosomes activated
RhoA and Notch signaling in cancercells through their ADAM10 activity. No
analysis of MMP, ADAM or TIMP gene
expression was reported in this setting
to clearly link the production of
pro-tumorigenic exosomes to
proteinase dysregulation. However,
three different sets of CAFs isolated
from lung cancer patients showed a
robust downregulation of all four TIMP
genes, suggesting that loss of TIMP in
cancer stroma may contribute to the
emergence and tumor-promoting
abilities of CAFs in human disease.
Since independent genetic events
targeting all four TIMPs are very
unlikely in a clinical setting, a possible
alternative for TIMP silencing in CAFs
could be via epigenetic or
post-translational modifications.
Alternatively, non-cell-autonomous
mechanisms may also operate and
fibroblast activation may be driven by
local variations in the extracellular
levels of proteases and TIMPs,
regardless of their origin. Further
analysis will be required to explore
these possibilities. Such studies would
increase our understanding of thespecific role of metalloproteinases in
cancer progression and regulation of
the tumor microenvironment.
Considering that MMP intervention
strategies have all failed in clinical trials
[16], these analyses could have
important therapeutic implications.
The findings reported by Shimoda
et al. [6] add to the current
understanding of molecular regulators
of CAF emergence, but they also raise
new questions. In particular, detailed
mechanistic description of the
molecular events responsible for the
CAF-like state after Timp1–4 deletion
is needed. Enhanced proteinase
activity can release latent growth
factors and chemokines from the
ECM [7] that may affect fibroblast
activation. Alternatively, unleashing
extracellular proteinase activity may
lead to matrix stiffening, which has
been shown to promote CAF
emergence [17]. Moreover, TIMPs can
also function by regulating key
signaling pathways [7,8]. Analysis of
the signaling and transcriptional
rearrangements in response to
Timp1–4 deletion may assist in
clarifying this point. A thorough
characterization of these events will
allow a more detailed investigation of
the CAF-like phenotype, whilst
integration of the adaptations elicited
by Timp1–4 loss in relation to other CAF
models [14,17–20] may increase our
current understanding of CAF biology
and lead to refined prognostic
signatures, markers and targets to
translate into the clinic.
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